Cost-effectiveness of three strategies for second-line erlotinib initiation in non small-cell lung cancer: the ERMETIC Study Part 3

  • Etude concernée: ERMETIC
  • Auteurs / Authors: Borget I, Cadranel J, Pignon JP, Quoix E, Coudert B, Westeel V, Dansin E, Madelaine J, Madroszyk A, Friard S, Daniel C, Morin F, Chouaid C; the ERMETIC Collaborative Group
  • Journal / Conference: European Respiratory Journal
  • Année / Year: 2012
  • PMID:  21659409
  • Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/21659409